NSE: IPCALAB | BSE: 524494

Mid-range Performer

Download real time

1339.00 22.00 (1.67%)

137.3K NSE+BSE Volume

NSE 30 Sep, 2025 3:31 PM (IST)

33,971

Market Cap

High in industry

0.8

Beta 1Year

Very Low volatility

Ipca Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for IPCALAB, BSE:524494 Ipca Laboratories Ltd.

Ipca Laboratories Ltd.

30 May 2019, 12:00AM

1339.00

1.67%

Cost headwinds receding; Generics/API outlook promising

Buy: Ipca Laboratories Ltd.

Motilal Oswal

Gross margin expanded 45bp YoY to 68% due to a better product mix. Reduced remediation cost (INR40m v/s INR100m in 4QFY18) and better operating leverage led to lower other expenses (-520bp YoY). As a result, EBITDA margin expanded at an even higher rate of 590bp YoY to 20.9% (our estimate: 17.4%). EBITDA was up 49% YoY at INR1.7b (our estimate: INR1.5b), while PAT increased 71% YoY to INR1b (our estimate: INR873m)....

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

02 May 2019

1339.00

1.67%

Ipca Labs

Buy: Ipca Laboratories Ltd.

Sharekhan

Ipca's major customer. The regulatory hurdle at distributor's end is now resolved and hence we expect this business to pick up gradually. Also, Ipca has been re-selected as the panel supplier for anti-malarial medicines to the global fund pooled procurement mechanism and for private sector co-payment mechanisms for an initial period of three years in FY19. Thus, the exports...

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

22 Apr 2019

1339.00

1.67%

Promising outlook for the next 2-3 years

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Sustained outperformance in branded domestic formulation (DF) space coupled with enhanced opportunities in the API segment and additional business from institutional Anti-Malaria segment shows that IPCA has enough headroom to be on a strong earnings trajectory over the next 2-3 years

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

06 Mar 2019

1339.00

1.67%

Management Meet Update - Enhanced visibility of multiple growth drivers

Buy: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

We met IPCA management, who charted out its vision to achieve a resolution Change in Estimates | Target | Reco with USFDA and turn around its business verticals which had faced challenges since CY15. IPCA's institutional tender business for anti-malaria...

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

14 Feb 2019

1339.00

1.67%

IPCA Labs: Margin improvement due to product mix and lower overheads due to forex

Buy: Ipca Laboratories Ltd.

Recommendation Target

Karvy

Margin improvement due to product mix and lower overheads due to forex: In Q3FY19, total revenues of IPCA Labs increased by 10.2%YoY to Rs 9476 mn(our estimates Rs 10450 mn) mainly due to increase in export formulationsand API.

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

13 Feb 2019

1339.00

1.67%

IPCA Laboratories

Buy: Ipca Laboratories Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Q3FY19 results were a comprehensive beat vis-a-vis I-direct estimates on the profitability front due to strong EBITDA margins (24.5% vs. I-direct estimate of 17.7%). Revenues grew 10.3% YoY to | 947.6 crore (I-direct estimate: | 939.1 crore) due to 10% growth in domestic formulations to | 421.6 crore EBITDA margins improved 569 bps YoY to 24.5% (I-direct estimate: 17.7%) due forex gain, strong gross margins and lower employee...

Number of FII/FPI investors decreased from 294 to 270 in Jun 2025 qtr

Ipca Laboratories Ltd.

15 Nov 2018

1339.00

1.67%

IPCA Laboratories

Buy: Ipca Laboratories Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Q2FY19 results were higher than I-direct estimates on all fronts. Revenues grew 15.4% YoY to | 997.8 crore (I-direct estimate: | 950.5 crore) due to 23.2% growth in export formulations to | 288.3 crore (Idirect estimate: | 282.9 crore). Domestic formulations grew 10.3% YoY to | 468.6 crore (I-direct estimate: | 446.0 crore) EBITDA margins remained at ~17% but came in higher then I-direct estimates of 15.5% mainly due to a strong gross margin performance. EBITDA grew 15.9% YoY to | 172.8 crore...

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

15 Nov 2018

1339.00

1.67%

IPCA Labs: Better revenue traction and margins

Hold: Ipca Laboratories Ltd.

Recommendation Target

Karvy

Better revenue traction and margins: In Q2FY19, total revenues of IPCA Labs increased by 15.4%YoY to Rs 9978 mn(our estimates Rs 9596 mn) mainly due to increase in domestic as well asexport formulations.

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

20 Aug 2018

1339.00

1.67%

Adjusted for one-time costs, IPCA results were below estimates. Revenue came in at Rs8.6b...

Hold: Ipca Laboratories Ltd.

Target

Emkay

Adjusted for one-time costs, IPCA results were below estimates. Revenue came in at Rs8.6bn against our estimate of Rs8.5bn while EBITDA stood at Rs1.4bn against our estimate of Rs1.5bn. PAT came in at Rs655mn against our estimate of Rs883mn. The domestic malaria season has had a weak uptake till date and all hopes hinge on the monsoon picking up later in the season. In the exports business, the next key trigger will be the resumption of the institutional tender business. growth, including revival in domestic and institutional generics business and the expected reinspection of plants by USFDA over the course of FY19....

Number of FII/FPI investors decreased from 294 to 270 in Jun 2025 qtr

Is Ipca Laboratories Ltd. worth buying?

367 Votes:

Buy 80.38%

Sell 9.81%

Hold 9.81%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf